News
Media
Puzzler
Publications
CME/CE
Resources
Conferences
Partnerships
Subscribe
Editorial

|Articles|November 1, 2000

Journal Club

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

TRAPEDS-1 evaluates tralokinumab in children with atopic dermatitis | Image Credit: © marishkaTR - stock.adobe.com.

TRAPEDS-1 evaluates tralokinumab in children with atopic dermatitis

ByMorgan Ebert, Executive Editor

July 11th 2026

Douglas Mack, MD, says THRIVE study could change early peanut allergy management

Douglas Mack, MD, says THRIVE study could change early peanut allergy management

ByDouglas Mack, MD, MSc, FRCPC

July 10th 2026

ACIP dropped MMRV coverage. New data show it was a lifeline for VFC-eligible kids | Image credit: © Leigh Prather - stock.adobe.com.

ACIP dropped MMRV coverage. New data show it was a lifeline for VFC-eligible kids

ByMorgan Ebert, Executive Editor

July 10th 2026

Infliximab and adalimumab show comparable infection risk in pediatric IBD, cohort study finds | Image Credit: © Khunatorn - stock.adobe.com.

Infliximab and adalimumab show comparable infection risk in pediatric IBD

ByMorgan Ebert, Executive Editor

July 10th 2026

Douglas Mack, MD, shares details on the ongoing THRIVE study of epicutaneous immunotherapy for peanut allergy

Douglas Mack, MD, shares details on the ongoing THRIVE study of epicutaneous immunotherapy for peanut allergy

ByDouglas Mack, MD, MSc, FRCPC

July 9th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

ACIP dropped MMRV coverage. New data show it was a lifeline for VFC-eligible kids

TRAPEDS-1 evaluates tralokinumab in children with atopic dermatitis

FDA grants tegacorat orphan, rare pediatric disease status for DMD

Douglas Mack, MD, says THRIVE study could change early peanut allergy management

Douglas Mack, MD, shares details on the ongoing THRIVE study of epicutaneous immunotherapy for peanut allergy